Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity

EPMA Journal

Charles Swanton²  James Larkin¹  Rosalie Fisher¹ 

[1] Department of Medicine, Royal Marsden Hospital, London, UK;Cancer Research UK London Research Institute, Translational Cancer Therapeutics Laboratory, 44 Lincoln's Inn Fields, London WC2A 3LY, UK

关键词: Predictive biomarkers;    Personalised medicine;    Heterogeneity;    Renal cell carcinoma;   

Others  :  802193
DOI  :  10.1007/s13167-011-0137-3

 received in 2011-09-29, accepted in 2011-12-02,  发布年份 2011

【 摘 要 】

Recent years have seen major advances in the management of metastatic renal cell carcinoma (mRCC). The tyrosine kinase and mammalian target of rapamycin inhibitors have resulted in disease control and improved survival for many patients with mRCC, but they have not led to preventive, predictive or personalised medicine (PPPM). Failure to achieve this rests ultimately with inadequate knowledge of tissue and molecular heterogeneity; discovery of these drugs was based upon identification of pathogenic molecular pathways in RCC, but research into molecular factors which underpin drug response, resistance and selection of therapy for individual patients has lagged well behind clinical trials of drug development. This review will provide an overview of the development of targeted drug therapies for mRCC, will discuss the challenges which currently impede the delivery of PPPM, including identification of biomarkers, drug resistance and molecular heterogeneity, and will propose research methodologies and technologies required to overcome these obstacles.

【 授权许可】

   
2011 Fisher et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
• [2]Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-92.
• [3]Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Leibovich BC, et al.: A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003, 170:2225-32.
• [4]Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 1996, 335:865-75.
• [5]Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al.: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003, 97:1663-71.
• [6]Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-6.
• [7]Harris DT: Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983, 10:422-30.
• [8]Yagoda A, Bander NH: Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 1989, 44:338-45.
• [9]Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-96.
• [10]Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005, 25:CD001425.
• [11]McDermott DF, Ghebremichael M, Signoretti S, Margolin KA, Clark J, Sosman JA, et al.: The high-dose aldesleukin 'SELECT' trial in patients with metastatic renal cell carcinoma. J Clin Oncol 2010., 28Abstr 4514
• [12]Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-92.
• [13]Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-72.
• [14]Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-42.
• [15]Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-32.
• [16]Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-8.
• [17]Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.: Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011, 364:2507-16.
• [18]Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-703.
• [19]Larkin J, Gore M: Is advanced renal cell carcinoma becoming a chronic disease? Lancet 2010, 376:574-5.
• [20]Sauter G, Eble JN, Epstein JI, Sesterhenn IA: World Health Organisation classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC 2004.
• [21]Reuter VE, Tickoo SK: Differential diagnosis of renal tumours with clear cell histology. Pathology 2010, 42:374-83.
• [22]Cheng L, Williamson SR, Zhang S, Maclennan GT, Montironi R, Lopez-Beltran A: Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther 2010, 10:843-64.
• [23]Siebert R, Jacobi C, Matthiesen P, Zuhlke-Jenisch R, Potratz C, Zhang Y, et al.: Detection of deletions in the short arm of chromosome 3 in uncultured renal cell carcinomas by interphase cytogenetics. J Urol 1998, 160:534-9.
• [24]Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85-90.
• [25]Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22:4991-5004.
• [26]Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000, 97:10430-5.
• [27]Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al.: Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423-7.
• [28]Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13:680s-4s.
• [29]Krause DS, Van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-87.
• [30]Knebelmann B, Ananth S, Cohen HT, Sukhatme VP: Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998, 58:226-31.
• [31]Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al.: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002, 22:7004-14.
• [32]Averous J, Proud CG: When translation meets transformation: the mTOR story. Oncogene 2006, 25:6423-35.
• [33]Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010, 29:2746-52.
• [34]Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG: The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer 2011, 117:677-87.
• [35]Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P: The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008, 283:36542-52.
• [36]Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, et al.: Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008, 372:892-7.
• [37]Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al.: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-3.
• [38]Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al.: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-42.
• [39]Delahunt B, Eble JN: Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Modern Pathol 1997, 10:537-44.
• [40]Kovacs G, Kovacs A: Parenchymal abnormalities associated with papillary renal cell tumors. J Urol Pathol 1993, 1:301-12.
• [41]Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al.: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16:68-73.
• [42]Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al.: Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 1997, 94:11445-50.
• [43]Lubensky IA, Schmidt L, Zhuang Z, Weirich G, Pack S, Zambrano N, et al.: Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999, 155:517-26.
• [44]Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, et al.: Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005, 65:4598-606.
• [45]Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, et al.: Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003, 73:95-106.
• [46]Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F, et al.: Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008, 100:1260-2.
• [47]Yan H, Bigner DD, Velculescu V, Parsons DW: Mutant metabolic enzymes are at the origin of gliomas. Cancer Res 2009, 69:9157-9.
• [48]Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, et al.: HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005, 8:143-53.
• [49]Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al.: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
• [50]Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, et al.: Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007, 67:3171-6.
• [51]Kovacs A, Kovacs G: Low chromosome number in chromophobe renal cell carcinomas. Gene Chromosome Canc 1992, 4:267-8.
• [52]Yusenko MV, Zubakov D, Kovacs G: Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by Affymetrix GeneChip using pooled and individual tumours. Int J Biol Sci 2009, 5:517-27.
• [53]Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003, 22:847-52.
• [54]Pan CC, Chen PC, Chiang H: Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 2004, 121:878-83.
• [55]Schoenberg M, Cairns P, Brooks JD, Marshall FF, Epstein JI, Isaacs WB, et al.: Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Gene Chromosome Cancer 1995, 12:76-80.
• [56]Rakozy C, Schmahl GE, Bogner S, Storkel S: Low-grade tubularmucinous renal neoplasms: morphologic, immunohistochemical, and genetic features. Mod Pathol 2002, 15:1162-71.
• [57]Ferlicot S, Allory Y, Comperat E, Mege-Lechevalier F, Dimet S, Sibony M, et al.: Mucinous tubular and spindle cell carcinoma: a report of 15 cases and a review of the literature. Virchows Arch 2005, 447:978-83.
• [58]Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, et al.: A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 2001, 158:2089-96.
• [59]Argani P, Antonescu CR, Couturier J, Fournet JC, Sciot R, Debiec-Rychter M, et al.: PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol 2002, 26:1553-66.
• [60]Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, et al.: Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Modern Pathol 2009, 22:1016-22.
• [61]Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al.: Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010, 183:1309-15.
• [62]Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V: Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002, 20:2376-81.
• [63]de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al.: Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001, 25:275-84.
• [64]Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 23:832-41.
• [65]Dash A, Carver BS, Stasi J, Bajorin DF, Motzer RJ, Bosl GJ, et al.: The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer 2008, 112:800-5.
• [66]Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al.: Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009, 27:235-41.
• [67]Fisher RA, Pendeer A, Thillai K, Chowdhury S, Pickering LM, Rose SS, et al.: Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. J Clin Oncol 2011., 29Abstr 4630
• [68]Churchill E, Barney JD: Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol 1939, 142:468-73.
• [69]Russo P: Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol 2010, 28:295-301.
• [70]Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML: Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011, 117:2873-82.
• [71]Rini BI, Shaw V, Rosenberg JE, Kim ST, Chen I: Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitour Cancer 2006, 5:232-4.
• [72]Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, et al.: Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 2011, 185:439-44.
• [73]Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003, 2:471-8.
• [74]O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al.: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-605.
• [75]Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-24.
• [76]Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al.: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-63.
• [77]Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-109.
• [78]Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-34.
• [79]Castaneda CA, Gomez HL: Pazopanib: an antiangiogenic drug in perspective. Future Oncol 2009, 5:1335-48.
• [80]Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-8.
• [81]Sternberg CN, Hawkins RE, Szczylik C, Davis ID, Wagstaff J, McCann L, et al.: Randomized, double-blind phase III study of pazopanib in patients with advanced/metastatic renal cell carcinoma: final overall survival results. Ann Oncol 2010., 21Abstr LBA22
• [82]Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 2000, 103:253-62.
• [83]Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004, 24:200-16.
• [84]Harding MW: Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003, 9:2882-6.
• [85]Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al.: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001, 8:249-58.
• [86]Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, et al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122-7.
• [87]Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al.: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66:5549-54.
• [88]Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-81.
• [89]Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-56.
• [90]Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-34.
• [91]Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-11.
• [92]Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al.: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008, 26:5422-8.
• [93]Rini BI, Vogelzang NJ, Dumas MC, Wade 3rd JL, Taber DA, Stadler WM: Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 2000, 18:2419-26.
• [94]Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, et al.: A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 2008, 180:867-72.
• [95]Waters JS, Moss C, Pyle L, James M, Hackett S, A'Hern R, et al.: Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer 2004, 91:1763-8.
• [96]Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, et al.: A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer 2006, 107:1273-9.
• [97]Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM: Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 2011, 29:e203-5.
• [98]Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al.: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-75.
• [99]Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al.: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-96.
• [100]Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
• [101]Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al.: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006, 66:3381-5.
• [102]Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH Jr, et al.: Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-80.
• [103]Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al.: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26:127-31.
• [104]Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J: Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol 2009, 36(Suppl 3):S26-36.
• [105]Dutcher JP, de Souza P, McDermott D, Figlin RA, Berkenblit A, Thiele A, et al.: Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009, 26:202-9.
• [106]Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM: Sunitinib in papillary renal cell carcinoma: Results from a single-arm phase II study. J Clin Oncol 2010., 28Abstr 4604
• [107]Vickers MM, Heng DY: Prognostic and predictive biomarkers in renal cell carcinoma. Target Oncol 2010, 5:85-94.
• [108]Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, et al.: Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010, 70:1053-62.
• [109]Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, et al.: Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res 2008, 14:3699-705.
• [110]Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al.: von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 860:5.
• [111]Gad S, Sultan-Amar V, Meric JB, Izzedine H, Khayat D, et al.: Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatmetn in metastatic renal cell carcinoma: preliminary results. Targ Oncol 2007, 2:3-6.
• [112]Hutson TE, Davis ID, Macheils JH, de Souza PL, Baker K, Bordogna W, et al.: Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multikinase angiogenesis inhibitor. J Clin Oncol 2008., 26Abstr 5046
• [113]Carroll VA, Ashcroft M: Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006, 66:6264-70.
• [114]Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al.: HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14:435-46.
• [115]Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B: The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005, 11:1129-35.
• [116]Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B: Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006, 50:1272-7.
• [117]Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, et al.: Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007, 13:7388-93.
• [118]Dorevic G, Matusan-Ilijas K, Babarovic E, Hadzisejdic I, Grahovac M, Grahovac B, et al.: Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2009, 28:40.
• [119]Patel PH, Chadalavada RS, Ishill NM, Patil S, Reuter VE, Motzer RJ, et al.: Hypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC). J Clin Oncol 2008., 26Abstract 5008
• [120]Pena C, Lathia C, Shan M, Escudier B, Bukowski RM: Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010, 16:4853-63.
• [121]Negrier S, Chabaud S, Escudier B, Ravaud A, Chevreau C, Blay JY, et al.: Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J Clin Oncol 2007., 25Abstract 5044
• [122]Escudier BJ, Ravaud A, Négrier S, Szczylik C, Bellmunt Molins J, Bracarda S, et al.: Update on AVOREN trial in metastatic renal cell carcinoma: Efficacy and safety in subgroups of patients and pharmacokinetic analysis. J Clin Oncol 2008., 26Abstr 5025
• [123]Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, et al.: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-8.
• [124]Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al.: Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007, 5:32.
• [125]Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-11.
• [126]Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T: Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 2007, 100:556-60.
• [127]Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, et al.: Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol 2007, 25:4757-64.
• [128]Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005, 11:3714-21.
• [129]Pantuck AJ, Fang Z, Lui X, Seligson DB, Horvath S, Leppert JT, et al.: Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 2005., 23Abstr 4535
• [130]Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, et al.: Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitour Cancer 2007, 5:379-85.
• [131]Devarajan P: The promise of biomarkers for personalized renal cancer care. Kidney Int 2010, 77:755-7.
• [132]Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-24.
• [133]Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL, et al.: Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007, 22:101-8.
• [134]Devarajan P: Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther 2007, 5:463-70.
• [135]Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I, et al.: Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77:809-15.
• [136]Hutterer GC, Patard JJ, Colombel M, Belldegrun AS, Pfister C, Guille F, et al.: Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer 2007, 110:2428-33.
• [137]Abou Youssif T, Fahmy MA, Koumakpayi IH, Ayala F, Al Marzooqi S, Chen G, et al.: The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011, 117:290-300.
• [138]Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, et al.: Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009, 115:3651-60.
• [139]George D, Armstrong AJ, Halabi S: Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. J Clin Oncol 2010., 28Abstr 4631
• [140]Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, et al.: Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009, 27:746-53.
• [141]Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, et al.: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Gene Cancer 2010, 1:152-63.
• [142]Rini BI, Zhou M, Aydin H, Elson P, Maddala T, Knezevic D, et al.: Identification of prognostic genomic markers in patients with localised clear cell renal carcinoma. J Clin Oncol 2010., 28Abstr 4501
• [143]Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R: Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 2007, 25:845-51.
• [144]Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007, 52:1147-55.
• [145]Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, et al.: Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011, 29:2557-64.
• [146]Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al.: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-73.
• [147]Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, et al.: Association of diastolic blood pressure >= 90 mmHg with overall survival in patients treated with axitinib (AG-013736). J Clin Oncol 2008., 26Abstr 3543
• [148]Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, et al.: Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009, 20:393-4.
• [149]Rixe O, Dutcher J, Motzer R, Wilding G, Stadler WM, Garrett M, et al.: Diastolic blood pressure and pharmacokinetics as predictors of axitinib efficacy in metastatic renal cell cancer. J Clin Oncol 2009., 27Abstr 5045
• [150]Kim JJ, Vaziri SA, Elson P, Rini BI, Patel A, Basappa NS, et al.: VEGF single nucleotide polymorphisms (SNPs) and correlation to baseline and sunitinib-induced hypertension in patients with metastatic renal cell carcinoma. ASCO Genitourinary Cancers Symposium 2010Abstr 330
• [151]de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, et al.: Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008, 14:5548-54.
• [152]Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, et al.: Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008, 26:4572-8.
• [153]Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, et al.: Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010, 2:53.
• [154]Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
• [155]Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, et al.: Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010, 2:53.
• [156]Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al.: Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011, 71:1858-70.
• [157]Moch H, Schraml P, Bubendorf L, Richter J, Gasser TC, Mihatsch MJ, et al.: Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res 1998, 58:2304-9.
• [158]Gerlinger M, Swanton C: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 2010, 103:1139-43.
• [159]Lee AJ, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, et al.: Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011, 71:1858-70.